Compounds > bc-1215
Page last updated: 2024-11-13

bc-1215

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BC-1215: an Fbxo3 inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72201045
CHEMBL ID4549895
SCHEMBL ID16781356
MeSH IDM0590361

Synonyms (26)

Synonym
c26h26n4
bc-1215
1507370-20-8
SCHEMBL16781356
n,n'-bis[(4-pyridin-2-ylphenyl)methyl]ethane-1,2-diamine
HY-117937
bc 1215
gtpl12671
bc1215
n1,n2-bis[4-(2-pyridinyl)benzyl]-1,2-ethanediamine
AS-16457
EX-A4964
n1,n2-bis(4-(pyridin-2-yl)benzyl)ethane-1,2-diamine ,
n1,n2-bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine
mfcd28118991
AT11446
CS-0068629
n1,n2-bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine;
A900369
AKOS037643445
S0322
CHEMBL4549895
{[4-(pyridin-2-yl)phenyl]methyl}[2-({[4-(pyridin-2-yl)phenyl]methyl}amino)ethyl]amine
EN300-20140899
AC-36588
Z3301587999
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.35 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Cerebral Infarction, Middle Cerebral Artery
[description not available]		02.4110
Acute Ischemic Stroke
[description not available]		02.4110
Cerebral Ischemia
[description not available]		02.4110
Injury, Ischemia-Reperfusion
[description not available]		02.4110
Ischemic Stroke
Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.		02.4110
Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.		02.4110
Reperfusion Injury
Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.		02.4110
Infarction, Middle Cerebral Artery
NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.		02.4110
Acute Respiratory Distress Syndrome
[description not available]		02.1710
Respiratory Distress Syndrome
A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.		02.1710
Chronic Lung Injury
[description not available]		02.0810
Innate Inflammatory Response
[description not available]		02.0810
Infections, Orthomyxoviridae
[description not available]		02.0810
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		02.0810
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0810
Orthomyxoviridae Infections
Virus diseases caused by the ORTHOMYXOVIRIDAE.		02.0810
Allodynia
[description not available]		02.5220
Peripheral Nerve Diseases
[description not available]		02.1110
Peripheral Nervous System Diseases
Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.		02.1110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.1310
Nerve Pain
[description not available]		02.1310
Neuralgia
Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.		02.1310